Last updated: November 2, 2026
CADUET, Pfizer’s fixed-dose combination of amlodipine besylate and atorvastatin calcium, is a mature small-molecule product with limited remaining brand value. FDA approval came in 2004 for patients with hypertension and dyslipidemia who require treatment for both conditions.[1] The product’s commercial trajectory followed the loss of exclusivity for its two active ingredients, particularly atorvastatin, whose U.S. patent expiry triggered broad generic substitution beginning in 2011.
Caduet remains commercially relevant as a combination product, but its economics are generic-driven. Pfizer does not report standalone Caduet revenue in its public filings, preventing a reliable product-level revenue series. The available evidence supports a decline from branded cardiovascular-blockbuster economics to a low-margin, multi-manufacturer generic market.
What is CADUET and how does it compete in the cardiovascular market?
CADUET combines:
| Component |
Drug class |
Primary role |
| Amlodipine besylate |
Dihydropyridine calcium-channel blocker |
Blood-pressure reduction |
| Atorvastatin calcium |
HMG-CoA reductase inhibitor |
LDL-cholesterol reduction |
The product is available in multiple strengths pairing amlodipine with atorvastatin. Its commercial proposition is adherence simplification: one tablet replaces separate antihypertensive and lipid-lowering prescriptions.
Caduet competes with separate generic amlodipine and atorvastatin tablets, which are usually cheaper and offer greater dosing flexibility. That substitution limits the pricing power of the fixed-dose combination. The combination can remain attractive for patients already stabilized on both ingredients, but physicians and payers can replicate the regimen with low-cost generics.
How does CADUET compare with separate amlodipine and atorvastatin?
| Factor |
CADUET |
Separate generic therapy |
| Pill burden |
One tablet |
Two tablets |
| Dosing flexibility |
Limited to marketed combinations |
Broad |
| Ingredient cost |
Usually higher than separate generics |
Very low |
| Adherence potential |
Better for selected patients |
More complex regimen |
| Reimbursement position |
Vulnerable to formulary substitution |
Generally preferred |
| Patent exposure |
Combination-product history |
Ingredient patents expired |
The combination’s principal commercial advantage is convenience. Its principal weakness is that generic buyers can reproduce the pharmacologic regimen at low cost.
When did CADUET lose exclusivity?
Caduet lost meaningful U.S. market exclusivity through the expiration of the underlying ingredient patents and the subsequent approval of generic alternatives.
| Milestone |
Approximate timing |
Commercial effect |
| FDA approval of Caduet |
2004 |
Initiated branded combination launch |
| Norvasc amlodipine exclusivity erosion |
2007 onward |
Reduced value of the antihypertensive component |
| Lipitor atorvastatin patent expiry |
November 2011 |
Opened the largest substitution pathway |
| Generic atorvastatin expansion |
2011-2012 |
Accelerated payer and pharmacy substitution |
| Generic amlodipine/atorvastatin combinations |
2012 onward |
Directly eroded Caduet demand |
| Mature generic market |
2013 onward |
Shifted economics toward volume and low price |
Atorvastatin was the more important commercial driver. Lipitor generated more than $9 billion in Pfizer revenue in 2011 before losing U.S. exclusivity.[2] Once generic atorvastatin entered, the value of a branded fixed-dose combination containing atorvastatin declined sharply.
The FDA Orange Book should be treated as the controlling source for the current listed patents, approved strengths, and regulatory status. Legacy combination-product patents did not preserve meaningful market exclusivity after broad generic access to the underlying ingredients and combination equivalents.[3]
What is the Orange Book status of CADUET?
Caduet was approved under NDA 021366. The product is a conventional oral tablet rather than a biologic, complex injectable, or drug-device combination.[1] Its regulatory profile is therefore governed by the abbreviated new drug application pathway for generic competitors.
The commercial implications are straightforward:
- Generic manufacturers can rely on the FDA’s finding of safety and efficacy for the listed reference product.
- ANDA applicants can challenge listed patents through Paragraph IV certifications or wait for patent expiry.
- Approved generic combinations can compete directly with the branded product.
- No biosimilar pathway applies because Caduet is a chemically synthesized small-molecule product.
Caduet’s Orange Book position is materially weaker than that of a product with an active, commercially meaningful composition-of-matter patent. The relevant market is now controlled by generic approval density, wholesaler supply, payer contracts, and pharmacy substitution.
Which companies are challenging CADUET through generic competition?
Generic competition has come from companies active in the amlodipine and atorvastatin markets, including large generic manufacturers and authorized or contract suppliers. The market has included manufacturers such as Teva, Mylan, Sandoz, Dr. Reddy’s Laboratories, Torrent Pharmaceuticals, and other ANDA sponsors, depending on strength, dosage form, and period.
The precise competitive set changes because generic approvals, marketing status, product discontinuations, and labeler ownership change over time. FDA listings should be used to identify currently marketed suppliers by strength.
What Paragraph IV challenges affected CADUET?
Paragraph IV litigation is most economically significant before generic launch, when a challenger can obtain market exclusivity or establish a launch date against the brand. For a product as old as Caduet, the core commercial impact of any early Paragraph IV dispute has already occurred.
The principal market event was the erosion of atorvastatin exclusivity in 2011. Generic atorvastatin approvals materially reduced the value of the atorvastatin component before the Caduet combination market fully matured. Later generic combination approvals eliminated most practical barriers to substitution.
Publicly disclosed litigation involving legacy Lipitor and amlodipine patents is more commercially significant than later disputes over Caduet itself. The relevant litigation question is whether a patent could delay direct combination-generic entry. It could not preserve the broader branded market once physicians and payers could use separate generic components.
What patents protect CADUET?
Caduet historically relied on a combination of ingredient, formulation, and combination-use protection. The principal patent categories were:
| Patent category |
Scope |
Current commercial relevance |
| Amlodipine patents |
Calcium-channel blocker compound and use |
Expired or commercially exhausted |
| Atorvastatin patents |
Statin compound and use |
U.S. exclusivity ended in 2011 |
| Combination patents |
Amlodipine plus atorvastatin composition |
Legacy protection; limited current value |
| Formulation patents |
Tablet composition, salts, stability, or manufacturing |
Potentially narrow and generally expired or circumventable |
| Method-of-use patents |
Treating hypertension and hyperlipidemia |
Weak against routine generic substitution |
| Pediatric exclusivity |
Regulatory extension tied to qualifying patents |
Historical only |
The patent estate was not strong enough to support durable post-2011 branded pricing. A combination patent can create a barrier to an exact fixed-dose generic, but it does not prevent physicians from prescribing the two active ingredients separately. That substitution route is particularly important for Caduet because both components are inexpensive and widely available.
What formulations are protected by CADUET patents?
Caduet’s commercial formulation is an immediate-release oral tablet containing amlodipine and atorvastatin. Any formulation protection would generally focus on:
- The combination of the two active ingredients;
- Specific dosage ratios;
- Salt forms or crystalline forms;
- Tablet excipients and stability;
- Manufacturing processes.
These claims are narrower than a composition-of-matter patent covering a novel active ingredient. Generic manufacturers can often avoid narrow formulation claims through different excipients, manufacturing conditions, dosage combinations, or separate-tablet products.
How strong is the CADUET patent estate?
The current patent estate is weak from an exclusivity and litigation perspective.
| Strength factor |
Assessment |
| Active ingredient protection |
Expired |
| Combination protection |
Legacy and narrow |
| Formulation differentiation |
Limited |
| Switching barrier |
Low |
| Generic substitution risk |
Very high |
| Biosimilar risk |
Not applicable |
| Probability of durable branded pricing |
Very low |
Caduet does not have the characteristics of a protected specialty product. It has no biologic manufacturing complexity, no injection-device barrier, no cold-chain requirement, and no clinically differentiated delivery system. Generic companies can manufacture the active ingredients at scale using established processes.
What is the financial trajectory for CADUET?
Pfizer’s public reporting does not provide a standalone Caduet revenue line. The company reports selected products and business segments, but Caduet is not disclosed as an individually material product in recent filings.[4]
The financial trajectory can therefore be divided into four phases:
1. Launch and adoption: 2004-2007
Caduet benefited from Pfizer’s cardiovascular sales infrastructure and the commercial strength of Norvasc and Lipitor. The product targeted patients needing treatment for both hypertension and high cholesterol. Revenue likely reflected branded pricing and physician familiarity, although Pfizer did not provide a consistent standalone public revenue series.
2. Early erosion: 2007-2011
Generic amlodipine reduced the value of the antihypertensive component. Caduet still retained some value because atorvastatin remained protected in the United States. The product’s pricing power was already under pressure, but the combination continued to leverage Lipitor’s brand franchise.
3. Major decline: 2011-2013
Generic atorvastatin entered the U.S. market after Lipitor’s patent expiry. This was the decisive financial inflection point. Pharmacies and payers could replace Caduet with generic atorvastatin, generic amlodipine, or a generic fixed-dose combination. Brand prescriptions and net price declined rapidly.
4. Mature generic phase: 2014 onward
The market became volume-oriented and price-sensitive. Any remaining Pfizer revenue would be expected to come from residual branded prescriptions, contracted supply, or limited distribution rather than protected pricing. Generic manufacturers compete on acquisition cost, availability, wholesaler relationships, and formulary positioning.
What revenue exposure does CADUET create for Pfizer?
Caduet is unlikely to represent material revenue exposure for Pfizer relative to its current portfolio. The product’s principal financial risks are:
- Continued conversion to separate generic tablets;
- Generic fixed-dose combination substitution;
- Low reimbursement for branded prescriptions;
- Product discontinuation or limited commercial availability;
- Loss of prescriber attention to newer cardiovascular therapies.
Its residual value may include brand recognition, manufacturing rights, and portfolio continuity. Those factors do not offset the loss of exclusivity.
Pfizer’s historical Lipitor exposure was substantial, but Caduet represented only a fraction of the value of the standalone statin franchise. The combination product extended convenience, not the underlying blockbuster economics.
What generic launch scenarios exist for CADUET?
Direct fixed-dose combination launch
A generic manufacturer markets the same active ingredients in an approved combination strength. This is the closest substitute and creates the greatest direct pressure on Caduet.
Separate-tablet substitution
A pharmacist or prescriber uses generic amlodipine and atorvastatin as separate prescriptions. This option usually provides the lowest cost and the broadest dose flexibility.
Brand retention in adherence-sensitive patients
Some patients remain on Caduet because of established control, convenience, or prescription inertia. This segment is unlikely to support meaningful premium pricing without favorable insurance coverage.
Supply-constrained generic pricing
Temporary shortages or limited supplier participation can increase generic prices. Such effects are procurement-driven and do not restore patent-based exclusivity.
What patent litigation and settlement agreements affect CADUET?
The most important historical litigation concerned patents for Lipitor, atorvastatin, and related cardiovascular products rather than a durable post-exclusivity dispute over Caduet. Pfizer and Ranbaxy reached a widely reported settlement concerning generic Lipitor, with U.S. generic entry permitted in November 2011, before the full statutory patent term would otherwise have ended.[5]
That settlement accelerated the timing of generic atorvastatin availability and established the market’s principal loss-of-exclusivity date. Once atorvastatin became broadly generic, Caduet faced structural substitution that a combination-product patent could not fully block.
No current settlement is likely to restore commercial exclusivity for Caduet. Any remaining litigation would have limited value unless it involved a currently marketed, commercially important formulation patent, which the public record does not indicate.
How does CADUET compare with newer cardiovascular products?
| Product type |
Patent strength |
Pricing potential |
Generic risk |
Commercial position |
| Caduet |
Low |
Low |
Very high |
Mature generic market |
| Standalone amlodipine |
None meaningful |
Very low |
Very high |
Commodity generic |
| Standalone atorvastatin |
None meaningful |
Very low |
Very high |
Large generic market |
| PCSK9 inhibitors |
Stronger active-product and biologic positioning |
Higher |
Lower near term |
Specialty lipid management |
| SGLT2 inhibitors |
Active branded patent estates |
Higher |
Moderate until expiry |
Cardiometabolic growth market |
| GLP-1 therapies |
Strong current commercial protection |
High |
Low near term |
High-growth metabolic market |
Caduet remains useful clinically for selected patients, but it has no structural advantage against newer therapies in growth, pricing, or patent durability.
What is the outlook for CADUET?
Caduet’s outlook is stable but economically limited. The product is unlikely to generate meaningful incremental growth because:
- Both active ingredients are mature generics;
- The fixed-dose combination faces substitution by separate tablets;
- The product has no biologic or device-based barrier;
- Major payer incentives favor low-cost generic therapy;
- Pfizer does not identify Caduet as a material current revenue driver.
The principal opportunity is not price expansion. It is efficient supply, retention of adherence-sensitive patients, and participation in generic or authorized-generic channels.
Key Takeaways
- Caduet combines amlodipine and atorvastatin in a fixed-dose oral tablet.
- FDA approved the product in 2004 under NDA 021366.[1]
- The decisive loss of exclusivity occurred after atorvastatin generic entry in 2011.
- Generic amlodipine and atorvastatin can replicate the treatment regimen at lower cost.
- Caduet has no biosimilar risk because it is a small-molecule drug.
- Pfizer does not disclose standalone Caduet revenue, so product-level financial estimates are not publicly verifiable.
- The current patent estate has low ability to support price premiums or delay generic substitution.
- The product’s remaining commercial value is concentrated in adherence, convenience, and residual brand demand.
FAQs About CADUET Patents, Generics, and Market Value
Is CADUET still a branded product?
Caduet is a branded Pfizer product, but its commercial market is heavily exposed to generic amlodipine, atorvastatin, and fixed-dose combination alternatives.
Can a generic substitute separate amlodipine and atorvastatin for CADUET?
Yes. Separate generic prescriptions can reproduce the active ingredients, although substitution depends on the prescribed regimen, payer rules, and applicable pharmacy law.
Does CADUET have biosimilars?
No. Biosimilars apply to biological products. Caduet is a chemically synthesized small-molecule combination.
What caused the largest decline in CADUET sales?
The largest decline followed generic atorvastatin entry after Lipitor’s U.S. exclusivity ended in 2011. That event removed the principal protected component of the combination.
Is CADUET an attractive licensing or acquisition target?
Its value is likely limited to supply contracts, brand retention, manufacturing efficiency, or a broader generic cardiovascular portfolio. It does not have the patent duration or pricing power typically associated with an attractive innovative-drug licensing target.
References
- U.S. Food and Drug Administration. (2004). Caduet prescribing information and approval history, NDA 021366. FDA Drugs@FDA.
- Pfizer Inc. (2011). Annual report for fiscal year 2011. Pfizer.
- U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.
- Pfizer Inc. (2023). Annual report for fiscal year 2023. Pfizer.
- Federal Trade Commission. (2011). FTC closes investigation of agreement between Pfizer and Ranbaxy concerning generic Lipitor. Federal Trade Commission.
